Ipamorelin 2mg Human Growth Acetate Powder 170851-70-4 For Muscle Gain

Ipamorelin 2mg Human Growth Acetate Powder 170851-70-4 For Muscle Gain

1. Quick Detail:
Unit Size :2 mg/vial
Unit Quantity :1 Vial
CAS NO. 170851-70-4
Synonyms Ipamorelin
Molecular Formula C38H49N9O5
Molecular Weight 711.85
Sequence H-Aib-His-D-2-Nal-D-Phe-Lys-NH2
Appearance White Powder
Purity 98.49%
Identity (ESI-MS) 711.85±0.5
Source Chemical Synthesis
Storage Lyophilized Ipamorelin is stable at room temperature for 90 days,however it should be stored
in a freezer below -8C for any extended period of time. After reconstituting Ipamorelin should be
refrigerated at temperatures not to exceed 36 F.

2. Description:

Ipamorelin is a fascinating new muscle building discovery that is getting a lot of attention in the
bodybuilding world. It is a synthetic peptide that has powerful Growth Hormone releasing properties.
And these GH releasing properties are what is of interest to athletes and bodybuilders since they can
make a tremendous difference in the amount of muscle you can grow and how quickly you burn fat.
Ipamorelin is a penta-peptide. (Aib-His-D-2-Nal-D- Phe-Lys-NH2) And, the strength it displays may
very well make regular old Growth Hormone (GH) obsolete. But what athletes and bodybuilders
really want to know is what is this wonder peptide capable of doing, how is it used, and how does it
compare to the other GHRP peptides?
Athletes are taking Ipamorelin in a 200mcg -300mcg dosage, two or three times daily, using a tiny
insulin needle to inject. They usually start with the lower dose since side effects can include
headaches or what feels like a head-rush. Ipamorelin can be taken at anytime but taking it about
30-45 minutes before a workout would seem ideal because of the pulse in Growth Hormone
(GH) it creates allowing for maximum growth.
Studies on the effects of Ipamorelin on bone growth, body weight, and GH release showed some
interesting conclusions.In one experiment, various doses were administered over the course of 15
days to test the group's reactions.
There was a distinct and dose-dependent effect on body weight gain however,the treatment group did
not show a change in total IGF-I levels. Nor did the treatment group produce serum markers of bone
development. For example, the number of cells in the wide portion of the tibia (the shinbone) did
not change significantly. This is a good thing because it suggests muscle growth with less potential
for deformity of bone or cartilage.
The reaction of the pituitary to an aggressive i.v. dose of Ipamorelin showed that plasma GH levels
were notably reduced whereas they were unchanged after a comparable dose of GHRH. This is
actually a good thing as it suggests that Ipamorelin may not decrease your body's natural GH
production - further demonstrating that Ipamorelin is a selective GH releaser.
Ipamorelin does not induce hunger making it advantageous to those on a restricted calorie diet. And
obviously, Ipamorelin's side effects are enhanced when combined with anabolic steroids since they
too influence Growth Hormone/Insulin Growth Factor release and production.Another document
states that in healthy swine, Ipamorelin released GH with a consistency that is very comparable to
GHRP-6. Also noteworthy was that none of the GH releasers tested affected FSH, LH, PRL or
TSH blood serum plasma levels.
Ipamorelin in theory may increase Acetylchloine or Cortisol when used in higher dosages. However,
and increase in Acetylchloine or Cortisol is even more likely with GHRP-2 and GHRP-6. In fact,
in the case of Ipamorelin, there was little to no rise in Acetylcholine and Cortisol blood plasma levels
even at injections more than 200 times higher than the effective dosage for comparable GH release.
This clearly proves that Ipamorelin is the first successful GHRP receptor agonist or chemical that
binds to a receptor of a cell and triggers a response by that cell with a specific selectivity for the
promotion of GH release by itself.
Another advantage to Ipamorelin is that it doesn't cause sudden spikes in prolactin or cortisol as does
GHRP-2 and GHRP-6. Ipamorelin is slower in its delivery unlike GHRP's which spike GH levels
at a more rapid rate. The slower release is more natural and has a more sustained effect.
All in all it looks as if Ipamorelin is the new wave in GH releasing peptides. It appear to be more potent,
longer lasting and potentially safer to use in the long run. More studies are being conducted all the time
but as it stands, Ipamorelin looks like a serious contender in the arsenal of anabolic advancement.

3. Applications:
Ipamorelin is a selective growth hormone secretagogue and agonist of the ghrelin receptor. In
pentobarbital anaesthetised rats, ipamorelin released GH with a potency and efficacy comparable to
GHRP-6 (ED50 = 80±42 nmol/kg and Emax = 1545±250 ng GH/ml vs 115±36nmol/kg and
1167±120ng GH/ml). In conscious swine, ipamorelin released GH with an ED50 = 2.3±0.03 nmol/kg
and an Emax = 65±0.2 ng GH/ml plasma. Again, this was very similar to GHRP-6 (ED50 = 3.9±1.4 nmol/kg and Emax = 74±7ng GH/ml plasma). GHRP-2 displayed higher potency but lower efficacy (ED50 = 0.6 nmol/kg and Emax = 56±6 ng GH/ml plasma). The specificity for GH release was studied in swine.